Ribomic Inc. (TYO:4591)

Japan flag Japan · Delayed Price · Currency is JPY
67.00
-2.00 (-2.90%)
Jun 3, 2026, 3:30 PM JST
Market Cap3.75B -2.3%
Revenue (ttm)3.00M +50.0%
Net Income-1.15B
EPS-23.06
Shares Out 54.31M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,299,300
Open68.00
Previous Close69.00
Day's Range66.00 - 80.00
52-Week Range66.00 - 141.00
Beta0.17
Analystsn/a
Price Targetn/a
Earnings DateMay 14, 2026

About Ribomic

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Tokyo, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 25
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4591
Full Company Profile

Financial Performance

In fiscal year 2026, Ribomic's revenue was 3.00 million, an increase of 50.00% compared to the previous year's 2.00 million. Losses were -1.15 billion, 12.5% more than in 2025.

Financial Statements